Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REPORTED POSITIVE KT-621 (STAT6) PHASE 1 HEALTHY VOLUNTEER DATA SURPASSING KYMERA'S TARGET PRODUCT PROFILE, AND FURTHER VALIDATING ITS ORAL, DUPILUMAB-LIKE PROFILE

KYMERA THERAPEUTICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WATERTOWN, MASS., JUNE 26, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF $250.8 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. KYMERA IS SELLING 5,044,500 SHARES OF COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 655,500 SHARES OF COMMON STOCK IN THE OFFERING. THE SHARES OF COMMON STOCK ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $44.00 PER SHARE AND THE PRE-FUNDED WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $43.9999 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK, LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT. IN ADDITION, KYMERA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 855,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS TO KYMERA FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $250.8 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES PAYABLE BY KYMERA, EXCLUDING THE EXERCISE OF ANY PRE-FUNDED WARRANTS AND ASSUMING NO EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. ALL OF THE SECURITIES BEING SOLD IN THIS OFFERING ARE BEING OFFERED BY KYMERA. THE OFFERING IS EXPECTED TO CLOSE ON JUNE 30, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

KYMERA THERAPEUTICS ANNOUNCES PRICING OF $250 MILLION PUBLIC OFFERING

WATERTOWN, MASS., JUNE 25, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $250.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THIS OFFERING ARE BEING OFFERED BY KYMERA. IN ADDITION, KYMERA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $37.5 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

KYMERA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

SANOFI TO ADVANCE KYMERA'S NEXT-GENERATION ORAL IRAK4 DEGRADER DEVELOPMENT CANDIDATE, KT-485, INTO CLINICAL TESTING AND WILL NOT ADVANCE KT-474

KYMERA THERAPEUTICS ANNOUNCES SANOFI IRAK4 COLLABORATION UPDATE

FOSTER CITY, CALIF. & WATERTOWN, MASS.--(BUSINESS WIRE)--GILEAD SCIENCES, INC. (NASDAQ: GILD) AND KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO AN EXCLUSIVE OPTION AND LICENSE AGREEMENT TO ACCELERATE THE DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL MOLECULAR GLUE DEGRADER (MGD) PROGRAM TARGETING CYCLIN-DEPENDENT KINASE 2 (CDK2) WITH BROAD ONCOLOGY TREATMENT POTENTIAL INCLUDING IN BREAST CANCER AND OTHER SOLID TUMORS. CDK2-DIRECTED MGDS ARE A NEW TYPE OF D.

GILEAD SCIENCES AND KYMERA THERAPEUTICS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT TO DEVELOP NOVEL ORAL MOLECULAR GLUE CDK2 DEGRADERS

PHASE 1 HEALTHY VOLUNTEER DATA OF KT-621, A ONCE-A-DAY STAT6 DEGRADER, SURPASS KYMERA'S TARGET PRODUCT PROFILE, SIGNIFICANTLY DERISKING PROGRAM AND FURTHER VALIDATING ITS ORAL, BIOLOGICS-LIKE PROFILE

KYMERA THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER

COMPANY TO HOST VIDEO WEBCAST AT 8:00 A.M. ET ON MONDAY, JUNE 2, 2025 COMPANY TO HOST VIDEO WEBCAST AT 8:00 A.M. ET ON MONDAY, JUNE 2, 2025

KYMERA THERAPEUTICS TO ANNOUNCE KT-621 PHASE 1 HEALTHY VOLUNTEER TRIAL RESULTS ON JUNE 2, 2025

WATERTOWN, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN FIRESIDE CHATS AT THE FOLLOWING UPCOMING INVESTOR EVENTS:

KYMERA THERAPEUTICS TO PARTICIPATE IN UPCOMING JUNE INVESTOR CONFERENCES

KT-621, A POTENT, SELECTIVE, ORAL STAT6 DEGRADER, DEMONSTRATED COMPARABLE OR SUPERIOR ACTIVITY TO DUPILUMAB IN A NEWLY DISCLOSED PRECLINICAL CHRONIC ASTHMA MODEL REVERSING DISEASE PROGRESSION

KYMERA THERAPEUTICS PRESENTS NEW PRECLINICAL DATA FOR KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE

IRF5 PROGRAM STRENGTHENS KYMERA'S ORAL IMMUNOLOGY PIPELINE WITH A COMPLEMENTARY MECHANISM TO EXPAND INTO RHEUMATIC AND OTHER AUTOIMMUNE DISEASES WITH A POTENTIAL BEST-IN-CLASS ORAL DRUG

KYMERA THERAPEUTICS EXPANDS INDUSTRY LEADING IMMUNOLOGY PIPELINE WITH NEW FIRST-IN-CLASS, ORAL IRF5 DEGRADER PROGRAM WITH POTENTIAL TO ADDRESS MULTIPLE IMMUNO-INFLAMMATORY DISEASES

Kymera Therapeutics, Inc.

KYMR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Kymera Therapeutics, Inc.

KYMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

KYMR